Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4xCD3) ImmTAC targeting MAGE-A4-expressing malignancies.
A new T cell-redirecting therapy shows anti-tumor activity across multiple solid cancers with a manageable safety profile, opening possibilities for patients with MAGE-A4-positive tumors.
This multicenter Phase 1/2 trial evaluated IMC-C103C across MAGE-A4-positive solid tumors, establishing dose-dependent antitumor activity with a safety profile consistent with T cell-redirecting therapies. Results position IMC-C103C as a promising first-in-class ImmTAC agent with activity across multiple solid tumor types defined by shared MAGE-A4 expression.
What the study was
- Study design
- Phase I/II clinical trial, multicenter
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- J Immunother Cancer
Why it surfaced
First-in-class ImmTAC TCR bispecific Phase I/II multicenter trial in MAGE-A4+ solid tumors; mechanistically novel; J Immunother Cancer indexed MEDLINE; directly actionable intelligence for immuno-oncology pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.